Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer

Wang,Jun; Yang,Zi-Rong; Guo,Xu-Feng; Song,Jia; Zhang,Ji‑Xiang; Wang,Jing; Dong,Wei-Guo

doi:10.3892/mmr.2014.2539

Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer

Authors:
- Jun Wang
- Zi-Rong Yang
- Xu-Feng Guo
- Jia Song
- Ji‑Xiang Zhang
- Jing Wang
- Wei-Guo Dong
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: September 5, 2014 https://doi.org/10.3892/mmr.2014.2539
Pages: 2535-2541

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Puerarin is an isoflavone derived from kudzu roots with a wide range of biological and medicinal properties. The aim of the present study was to investigate the inhibitive effects of puerarin combined with 5‑fluorouracil (5‑FU) on Eca‑109 esophageal cancer cells in vitro and in vivo. Inhibitive effects of the treatments on Eca‑109 cells were detected by cell counting kit‑8, Hoechst 33258 staining and flow cytometry. A tumor xenograft model was established in nude mice. Puerarin and 5‑FU, administered either in combination or individually, were injected into mice and the inhibitive effects along with any side effects were observed. Apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Puerarin and 5‑FU, administered as combined treatment or individual drugs, significantly inhibited proliferation and induced marked apoptosis. The mean growth inhibition rate (± standard deviation) reached 87.27±5.37% and the apoptotic rate at 48 h reached 36.18±1.24% in the combined treatment group. The percentages of apoptotic cells induced by puerarin and 5‑FU (combined or alone) were significantly higher than those of the control group (P<0.05). Puerarin or 5‑FU alone significantly inhibited the growth of xenograft tumors in comparison to the control group (P<0.05), with inhibition rates of 76.93 and 72.21%, respectively. The drugs combined exhibited a significantly greater effect than either drug alone (P<0.05), with the tumor inhibition rate reaching 89.06%. During the course of chemotherapy, no evident side effects were observed. The results suggested that the combined inhibitive effects of puerarin and 5‑FU were greater than the effects of the agents used individually. In addition, puerarin combined with 5‑FU exhibited synergistic effects at lower concentrations and promoted apoptosis, but did not increase the side effects of chemotherapy, which indicated that puerarin may be a safe and effective chemosensitive agent in the treatment of human esophageal cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
3	Tran GD, Sun XD, Abnet CC, et al: Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 113:456–463. 2005. View Article : Google Scholar
4	Allum WH, Stenning SP, Bancewicz J, et al: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
5	Song JX, Sze SC, Ng TB, et al: Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol. 139:698–711. 2012. View Article : Google Scholar : PubMed/NCBI
6	Xie W and Du L: Diabetes is an inflammatory disease: evidence from traditional Chinese medicines. Diabetes Obes Metab. 13:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhang NB, Huang ZG, Cui WD and Ding BP: Effects of puerarin on expression of cardiac Smad3 and Smad7 mRNA in spontaneously hypertensive rat. J Ethnopharmacol. 138:737–740. 2011. View Article : Google Scholar : PubMed/NCBI
8	Mori M, Aizawa T, Tokoro M, et al: Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women. Clin Exp Pharmacol Physiol. 31(Suppl 2): S39–S41. 2004. View Article : Google Scholar : PubMed/NCBI
9	Michihara S, Tanaka T, Uzawa Y, et al: Puerarin exerted anti-osteoporotic action independent of estrogen receptor-mediated pathway. J Nutr Sci Vitaminol. 58:202–209. 2012. View Article : Google Scholar : PubMed/NCBI
10	Benlhabib E, Baker JI, Keyler DE and Singh AK: Effects of purified puerarin on voluntary alcohol intake and alcohol withdrawal symptoms in P rats receiving free access to water and alcohol. J Med Food. 7:180–186. 2004. View Article : Google Scholar
11	Hertog MG, Feskens EJ, Hollman PC, Katan MB and Kromhout D: Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 342:1007–1011. 1993. View Article : Google Scholar : PubMed/NCBI
12	Wong KH, Li GQ, Li KM, et al: Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. J Ethnopharmacol. 134:584–607. 2011. View Article : Google Scholar : PubMed/NCBI
13	Tao HQ, Meng Q, Li MH, et al: HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia-reperfusion injury in rats. Naunyn Schmiedebergs Arch Pharmacol. 386:61–70. 2013.
14	Yu Z and Li W: Induction of apoptosis by puerarin in colon cancer HT-29 cells. Cancer Lett. 238:53–60. 2006. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, Ma Y, Zheng Y, et al: In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity. Int J Pharm. 441:728–735. 2013. View Article : Google Scholar : PubMed/NCBI
16	Li XR, Zhang QQ, Cui YH, et al: The growth influence on human esophageal cancer cells EC9706 induced by puerarin. Journal of Oncology Medicine. 2010.1922–1924. 2010.(In Chinese).
17	Lin YJ, Hou YC, Lin CH, et al: Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells. Biochem Biophys Res Commun. 378:683–688. 2009. View Article : Google Scholar : PubMed/NCBI
18	Hien TT, Kim HG, Han EH, et al: Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res. 54:918–928. 2010. View Article : Google Scholar
19	Yu C, Li Y, Chen H, et al: Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity. Food Chem Toxicol. 46:3671–3676. 2008. View Article : Google Scholar : PubMed/NCBI
20	Awad ME, Abdel-Rahman MS and Hassan SA: Acrylamide toxicity in isolated rat hepatocytes. Toxicol in Vitro. 12:699–704. 1998. View Article : Google Scholar : PubMed/NCBI
21	Chen M and Wang J: Initiator caspases in apoptosis signaling pathways. Apoptosis. 7:313–319. 2002. View Article : Google Scholar
22	Green DR: Apoptotic pathways: ten minutes to dead. Cell. 121:671–674. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yeh KH, Yeh SH, Hsu CH, et al: Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer. 83:1510–1515. 2000. View Article : Google Scholar : PubMed/NCBI
24	Wu XX, Kakehi Y, Mizutani Y, et al: Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol. 19:19–24. 2001.PubMed/NCBI
25	Ikebukuro K, Adachi Y, Toki J, et al: Morphological change, loss of deltapsi(m) and activation of caspases upon apoptosis of colorectal adenocarcinoma induced by 5-FU. Cancer Lett. 153:101–108. 2000. View Article : Google Scholar : PubMed/NCBI
26	Shears LL, Ribeiro U, Kane J, et al: apoptosis in esophageal cancer following induction chemoradiotherapy. J Surg Res. 79:20–24. 1998. View Article : Google Scholar : PubMed/NCBI
27	Matsuhashi N, Saio M, Matsuo A, et al: The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time-and p53 expression-dependency of anti-cancer drugs. Oncol Rep. 14:609–615. 2005.PubMed/NCBI
28	Tian F, Fan T, Zhang Y, et al: Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 44:847–855. 2012.PubMed/NCBI